Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.
Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.
复制标题
益生菌类型、剂量和治疗持续时间对罗马 III 标准诊断的肠易激综合征的影响：荟萃分析
DOI：
10.1186/s12876-016-0470-z
复制
发表时间：
2016-06-13
影响因子：
2.4
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Zhang Y;Li L;Guo C;Mu D;Feng B;Zuo X;Li Y
肠易激综合征(IBS)是最常见的功能性消化系统疾病之一，全世界11.2%的人受到影响。此前的研究表明，益生菌治疗可能使IBS患者受益。然而，益生菌对IBS的作用以及合适的类型、剂量和治疗时间仍然不清楚。本研究的目的是通过随机对照试验(RCT)的荟萃分析，评估不同益生菌类型、剂量和治疗持续时间对罗马III标准诊断的IBS患者的疗效。方法检索Medline、EMBASE和Cochrane Central Register of Control Trials，直至2015年10月。随机对照试验，包括比较益生菌和安慰剂对罗马III标准诊断的IBS患者的影响，都是合格的。二分资料合并得到相对危险度(RR)，可信区间(CI)为95%，连续资料用标准化均数差(SMD)合并，可信区间(CI)为95%。益生菌治疗在总体症状反应(RR：1.82，95%CI 1.27~2.60)和生活质量(QOL)(SMD：0.29，95%CI 0.08~0.50)方面比安慰剂治疗有更大的改善，但对个别IBS症状的改善不明显。单一益生菌、低剂量和短疗程在总体症状反应和生活质量方面更有效。结论益生菌治疗IBS是一种有效的药物治疗方法。低剂量和短疗程的单一益生菌似乎在改善总体症状反应和生活质量方面更有效，但这些效果仍需更多证据。
BackgroundIrritable bowel syndrome (IBS) is one of the most common functional gastroenterological diseases, affecting 11.2 % of people worldwide. Previous studies have shown that probiotic treatment may benefit IBS patients. However, the effect of probiotics and the appropriate type, dose, and treatment duration for IBS are still unclear. The aim of the current study was to assess the efficacy of different probiotic types, doses and treatment durations in IBS patients diagnosed by Rome III criteria via a meta-analysis of randomized controlled trials (RCTs).MethodsMedline, EMBASE, and the Cochrane Central Register of Controlled Trials up to October 2015 were searched. RCTs including comparisons between the effects of probiotics and placebo on IBS patients diagnosed by Rome III criteria were eligible. Dichotomous data were pooled to obtain the relative risk (RR) with a 95 % confidence interval (CI), whereas continuous data were pooled using a standardized mean difference (SMD) with a 95 % CI.ResultsTwenty-one RCTs were included in this meta-analysis. Probiotic therapy was associated with more improvement than placebo administration in overall symptom response (RR: 1.82, 95 % CI 1.27 to 2.60) and quality of life (QoL) (SMD: 0.29, 95 % CI 0.08 to 0.50), but not in individual IBS symptoms. Single probiotics, a low dose, and a short treatment duration were more effective with respect to overall symptom response and QoL. No differences were detected in individual IBS symptoms in the subgroup analyses.ConclusionProbiotics are an effective pharmacological therapy in IBS patients. Single probiotics at a low dose and with a short treatment duration appear to be more effective in improving overall symptom response and QoL, but more evidence for these effects is still needed.